 Vyant Bio NASDAQ:VYNT Inc ended its first quarter with 16.4 million after a busy three months that saw it progress the discovery of small molecule therapeutics to treat neurological diseases. In the period to March 31, 2022, the Cherry Hill, New Jersey-based company implemented an up to 14.5 million at the market financing vehicle with Canaccord Genuity TSX:CF, LSE:CF and another equity line of credit facility with Lincoln Park Capital for up to 15 million. 